FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196526437> ?p ?o ?g. }

• W3196526437 endingPage "479" @default.
• W3196526437 startingPage "475" @default.
• W3196526437 abstract "El conocimiento de los niveles de fármacos anti-TNFα puede modificar el tratamiento en pacientes con artritis reumatoide (AR) y espondiloartritis (EspA). Comparar los niveles de anti-TNFα en los pacientes con AR vs. EspA, en diferentes situaciones clínicas. Se realizó un estudio retrospectivo, observacional donde se midieron los niveles de anti-TNFα y la presencia de anticuerpos antifármacos en pacientes seleccionados consecutivamente, utilizando la técnica de ELISA. Se estudiaron 53, 73 y 78 pacientes en tratamiento con infliximab, adalimumab y etanercept, respectivamente. Los niveles medios de fármaco en pacientes con dosis estándar fueron: infliximab 2,2 μg/ml (1,4-5,2), adalimumab 4,9 μg/ml (0,8-8,9) y etanercept 3,1 μg/ml (2,3-4,4). No se encontraron diferencias en los niveles fármacos según la actividad de la enfermedad, sin embargo, hubo diferencias en los niveles de etanercept e infliximab según el uso de fármacos modificadores de la enfermedad sintéticos (FAMEsc). Los niveles de fármacos anti-TNFα se verán modificados por el tratamiento con FAMEsc. Knowledge of the levels of anti-TNFα drugs can modify treatment in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). To compare the levels of anti-TNFα in patients with RA vs SpA, in different clinical situations. A retrospective, observational study was conducted. Levels of anti-TNFα and the presence of anti-drug antibodies were measured in consecutively selected patients, using the ELISA technique. Fifty-three, 73 and 78 patients treated with infliximab, adalimumab and etanercept were studied, respectively. The median drug levels in patients using standard doses were infliximab 2.2 μg/ml (1.4-5.2), adalimumab 4.9 μg/ml (0.8-8.9) and etanercept 3.1 μg/ml (2.3-4.4). There were no differences in drug levels according to disease activity but we found differences in etanercept and infliximab levels according to DMARD use. Levels of anti-TNFα drugs will change with DMARD treatment." @default.
• W3196526437 created "2021-09-13" @default.
• W3196526437 creator A5063377350 @default.
• W3196526437 creator A5082537796 @default.
• W3196526437 date "2022-10-01" @default.
• W3196526437 modified "2023-09-25" @default.
• W3196526437 title "Niveles de fármacos anti-TNFα en pacientes con artritis reumatoide y espondiloartritis" @default.
• W3196526437 cites W1969216944 @default.
• W3196526437 cites W1979569684 @default.
• W3196526437 cites W2078886781 @default.
• W3196526437 cites W2111046066 @default.
• W3196526437 cites W2142617751 @default.
• W3196526437 cites W2150944237 @default.
• W3196526437 cites W2154640984 @default.
• W3196526437 cites W2179405517 @default.
• W3196526437 cites W2473657157 @default.
• W3196526437 cites W2620682544 @default.
• W3196526437 cites W2792586419 @default.
• W3196526437 cites W2899183091 @default.
• W3196526437 cites W2956648588 @default.
• W3196526437 cites W3000573092 @default.
• W3196526437 cites W3095158811 @default.
• W3196526437 doi "https://doi.org/10.1016/j.reuma.2021.06.001" @default.
• W3196526437 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34503928" @default.
• W3196526437 hasPublicationYear "2022" @default.
• W3196526437 type Work @default.
• W3196526437 sameAs 3196526437 @default.
• W3196526437 citedByCount "0" @default.
• W3196526437 crossrefType "journal-article" @default.
• W3196526437 hasAuthorship W3196526437A5063377350 @default.
• W3196526437 hasAuthorship W3196526437A5082537796 @default.
• W3196526437 hasConcept C126322002 @default.
• W3196526437 hasConcept C17991360 @default.
• W3196526437 hasConcept C2777138892 @default.
• W3196526437 hasConcept C2777226972 @default.
• W3196526437 hasConcept C2777575956 @default.
• W3196526437 hasConcept C2780132546 @default.
• W3196526437 hasConcept C3020084786 @default.
• W3196526437 hasConcept C71924100 @default.
• W3196526437 hasConceptScore W3196526437C126322002 @default.
• W3196526437 hasConceptScore W3196526437C17991360 @default.
• W3196526437 hasConceptScore W3196526437C2777138892 @default.
• W3196526437 hasConceptScore W3196526437C2777226972 @default.
• W3196526437 hasConceptScore W3196526437C2777575956 @default.
• W3196526437 hasConceptScore W3196526437C2780132546 @default.
• W3196526437 hasConceptScore W3196526437C3020084786 @default.
• W3196526437 hasConceptScore W3196526437C71924100 @default.
• W3196526437 hasIssue "8" @default.
• W3196526437 hasLocation W31965264371 @default.
• W3196526437 hasOpenAccess W3196526437 @default.
• W3196526437 hasPrimaryLocation W31965264371 @default.
• W3196526437 hasRelatedWork W1491634525 @default.
• W3196526437 hasRelatedWork W1973470095 @default.
• W3196526437 hasRelatedWork W2039662997 @default.
• W3196526437 hasRelatedWork W2087204357 @default.
• W3196526437 hasRelatedWork W2141436693 @default.
• W3196526437 hasRelatedWork W2169326936 @default.
• W3196526437 hasRelatedWork W2341567294 @default.
• W3196526437 hasRelatedWork W2342269472 @default.
• W3196526437 hasRelatedWork W236437798 @default.
• W3196526437 hasRelatedWork W2766107802 @default.
• W3196526437 hasVolume "18" @default.
• W3196526437 isParatext "false" @default.
• W3196526437 isRetracted "false" @default.
• W3196526437 magId "3196526437" @default.
• W3196526437 workType "article" @default.